Cambridge Heart
This article was originally published in The Gray Sheet
Executive Summary
Microvolt level T-wave alternans measured with the firm's CH2000 test system "was the only statistically significant predictor of sudden death" among seven different clinical measures evaluated in a study of 107 congestive heart failure (CHF) patients followed for 18 months, the firm reports. Published in the Aug. 19 issue of The Lancet, the study included patients with no prior history of sustained ventricular arrhythmias. The study shows the technology to be "the most effective non-invasive test to identify [CHF] patients at risk for developing life-threatening abnormal heart rhythms," the firm maintains. The CH2000 system was cleared by FDA in 1996, and labeling was expanded in April 1999 to include the prediction of risk for severe cardiac arrest
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.